Efcacy and safety of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin regimen for recurrent genotype 1 HCV infection after liver transplantation-multicenter, real-life, AMBer-Cee study

Authors
Category Primary study
JournalClinical and Experimental Hepatology
Year 2016
This article has no abstract
Epistemonikos ID: 56711e9ae8b7ce5796937c4b39ee2d72d8d898a3
First added on: Feb 08, 2025